Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GI DYNAMICS, INC.GID · Entity 141502 | Director | February 28, 2020 | March 05, 2020 |
| KIORA PHARMACEUTICALS INCKPRX · Entity 7940 | Director | June 10, 2026 | June 12, 2026 |
| LEXICON PHARMACEUTICALS, INC.LXRX · Entity 4970 | EVP, R&D | February 28, 2021 | March 02, 2021 |
| Skye Bioscience, Inc.SKYE · Entity 8098 | Director | February 29, 2024 | March 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GI DYNAMICS, INC.
Report date February 28, 2020 · Filed March 05, 2020
This filing explicitly reported no securities owned.
KIORA PHARMACEUTICALS INC
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.63 · Expires 2036-06-10 | Direct | 40,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 40,000 · Balance 40,000 F1: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027.
LEXICON PHARMACEUTICALS, INC.
Report date February 28, 2021 · Filed March 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 120,791 |
Ending reported balance
After 2021-02-28 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2021-02-28 · Exercise / conversion · Acquired 2,990 · Balance 72,334 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 2 · 2021-02-28 · Exercise / conversion · Acquired 9,727 · Balance 82,061 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 3 · 2021-02-28 · Exercise / conversion · Acquired 26,600 · Balance 108,661 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 4 · 2021-02-28 · Exercise / conversion · Acquired 28,690 · Balance 137,351 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 5 · 2021-02-28 · Tax withholding · Disposed 16,560 · Balance 120,791 F2: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-02-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-02-28 · Exercise / conversion · Disposed 2,990 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. F3: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-02-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-02-28 · Exercise / conversion · Disposed 9,727 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. F4: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 26,600 |
Reported balance
After 2021-02-28 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-02-28 · Exercise / conversion · Disposed 26,600 · Balance 26,600 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. F5: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 57,380 |
Reported balance
After 2021-02-28 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-02-28 · Exercise / conversion · Disposed 28,690 · Balance 57,380 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. F6: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock.
F2: Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
F3: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter.
F4: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2019 and vest an additional one third on February 28 of each of the two succeeding years thereafter.
F5: Restricted stock units vest with respect to one third of the shares subject to the restricted stock units on February 28, 2020 and vest an additional one third on February 28 of each of the two succeeding years thereafter.
F6: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.
Skye Bioscience, Inc.
Report date February 29, 2024 · Filed March 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.56 · Expires 2034-03-01 | Direct | 35,000 |
Reported balance
After 2024-02-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-29 · Grant · Acquired 35,000 · Balance 35,000 F1: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2017 Filed Jun 22, 2017 16:18 UTC | KIORA PHARMACEUTICALS INC EYEG · Entity 7940 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001144204-17-033622 · v469452_4.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: The Reporting Person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to 100% of the shares underlying the Option on June 21, 2018. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 21:29 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units (Phantom Stock) · Derivative | 11,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-005429 · form4.xml · derivative · entry 2 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,960 Underlying: Common Stock · 11,960 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. F3 · derivative.expiration_date: Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2018 and vest an additional 25% on February 28 of each of the three succeeding years thereafter. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 21:29 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 47,860 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0001127602-17-005429 · form4.xml · derivative · entry 1 TYLE PRAVEEN · CIK 0001296936 · EVP, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,860 Underlying: Common Stock · 47,860 shares Expires 2027-02-09 F1 · derivative.exercise_date: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (2/9/2018) and vests 1/48th per month for each month of service thereafter Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.